Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind study of SAL0114 in Chinese adults with major depressive disorder
CTR20240090Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0114 in major depressive disorder (MDD), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Mar 2024; status: active.
02
Drugs
SAL0114
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20240090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240090.